In contrast to ischemic cardiomyopathies which are more common in men, women are over-represented in diabetic cardiomyopathies. Diabetes is a risk factor for cardiovascular disease; however, there is a sexual dimorphism in this risk factor: heart disease is five times more common in diabetic women but only two-times more common in diabetic men. Heart failure with preserved ejection fraction, which is associated with metabolic syndrome, is also more prevalent in women. This review will examine potential mechanisms for the sex differences in metabolic cardiomyopathies. Sex differences in metabolism, calcium handling, nitric oxide, and structural proteins will be evaluated. Nitric oxide synthase and PPARa exhibit sex differences and have also been proposed to mediate the development of hypertrophy and heart failure. We focused on a role for these signalling pathways in regulating sex differences in metabolic cardiomyopathies.
Sex differences in cardiomyopathy and heart failure
There are many prominent sex differences in cardiovascular disease. Women generally develop coronary artery disease and myocardial infarction later than men. 1, 2 However diabetic cardiomyopathy, which is commonly defined as cardiomyopathy independent of vascular disease, is more prevalent in diabetic women than in diabetic men, 3 and heart failure with reduced ejection fraction (HFrEF) occurs more frequently in men, whereas heart failure with preserved ejection fraction (HFpEF) is equally present with HFrEF in women. 4, 5 The Framingham Heart Study reported a two-fold increase in HFpEF in females vs. males. 5 This sex difference is driven by an increase in HFrEF in males; females exhibit similar rates of HFpEF and HFrEF. 6 Dilated cardiomyopathy is more common in men, whereas concentric hypertrophy has increased prevalence in women. 7 Despite the findings that heart failure and cardiomyopathy are generally less prevalent in women, these cardiomyopathies with a metabolic link are more common in women than men. The basis for these sex differences in hypertrophy and heart failure are poorly understood. Metabolic cardiomyopathies are caused by pathological conditions which include familial metabolic diseases typically appearing in early childhood as well as systemic metabolic diseases which develop during adulthood. Regarding the latter, metabolic syndrome and type 2 diabetes mellitus represent the main cause of metabolic cardiomyopathy and are discussed herein.
Patients with chronic heart failure can be divided in two categories based on left ventricular ejection fraction. 8, 9 HFpEF has a strong link with metabolic syndrome, which includes insulin resistance, lipid disorders, obesity, and hypertension. 4, 10 Typically, patients with a previous myocardial infarction, which is more common in men, tend to develop HFrEF. 5, [11] [12] [13] Plasma brain natriuretic peptide (BNP) levels have diagnostic and prognostic value in heart failure. [14] [15] [16] [17] Patients with HFpEF typically have lower BNP than patients with HFrEF. 12, 18, 19 This is usually attributed to reduced wall stress in HFpEF. 20 At present, in contrast to HFrEF, no specific treatment has been shown to reduce morbidity or mortality in patients with HFpEF. 21 Although the term diabetic cardiomyopathy is often linked to HFpEF, epidemiological data suggest that the prevalence of diabetes is similar in HFrEF and HFpEF. 11, 13, 22 Diabetic cardiomyopathy is defined as ventricular dysfunction occurring in diabetic patients independent of a coronary heart disease or hypertension. 23, 24 It is well-established that diabetes and insulin resistance are risk factors for cardiomyopathy. [25] [26] [27] Cardiovascular disease is the primary cause of death associated with diabetes. Furthermore, patients with diabetic cardiomyopathy have increased left ventricular with diabetes, has often been attributed to an increase in vascular dysfunction and atherosclerosis. Emerging data suggest that diabetes can also directly result in alterations in cardiac metabolism, structure, and function and that these changes play an important role in the development of diabetic cardiomyopathy. There are several mechanisms by which diabetes can lead to cardiomyopathy; these include increased oxidative stress, lipotoxicity, fatty acid oxidation, and altered signalling related to insulin resistance. This review will focus on potential mechanisms for the sex differences in diabetic cardiomyopathy and HFpEF, both of which are more prevalent in women than men. [3] [4] [5] 10, [28] [29] [30] A role for sex differences in metabolism, calcium homeostasis, nitric oxide (NO), and structural proteins will be considered. This review is focused on sex differences in cardiomyocytes. Sex differences in vascular function are well-established and have been reviewed elsewhere.
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2. Potential targets for sex differences in diabetic cardiomyopathy and HFpEF
As discussed, although women account for less than half of the cases of heart failure in the US, they are over-represented in diabetic cardiomyopathy and HFpEF. What might account for these sex differences in cardiomyopathies? There are baseline sex differences in metabolism, calcium handling, nitric oxide, and structural proteins which could contribute to these sex differences in hypertrophy and heart failure. These baseline sex differences could interact differently with disease to result in sex differences in cardiomyopathies. As discussed later there are also a large number of sex differences in gene expression in the heart, [33] [34] [35] [36] [37] [38] [39] which likely underlie the sex differences in hypertrophy.
Metabolism
Metabolism contributes to the development of cardiac hypertrophy and heart failure. Many studies have reported sex differences in metabolism, both at baseline and with hypertrophy. Peterson et al. 40 reported baseline sex differences in myocardial glucose uptake. They further report that the detrimental effects of obesity and diabetes on glucose metabolism are more pronounced in men than in women. Banke et al. 41 reported sex differences in triglyceride dynamics in heart, and Devanathan et al. 42 reported baseline sex differences in acylcarnitine and triglyceride metabolism. A study of sex differences in glycogen levels showed that female mice had lower glycogen in the baseline fed condition, but with 48 h of starvation glycogen increased in females but not in males. 43 These data suggest sex differences in the regulation of glycogen and glycophagy. Interestingly, a proteomics approach by Yan et al. 44 reported agedependent differences between male and female monkey hearts in glycolytic and mitochondrial electron-transport pathways. They note that the changes in the old male monkeys are similar to changes that occur in disease and suggest that the lack of these changes in old female hearts is consistent with delayed cardiovascular risk in females. In a study on human patients, Lyons et al. 45 reported that men and women had different responses to metformin and other diabetic treatments. Metformin decreased fatty acid clearance in men but not in women. Consistent with these sex dependent differences in metabolism, type 2 diabetes increases the risk of cardiovascular disease to a greater extent in women than in men, 3 and Blondel et al. 46 reported sex-specific outcomes for diabetic patients who have percutaneous transluminal coronary angioplasty. Also of note, the Women's Health Initiative showed that hormone replacement therapy was associated with a significant improvement in insulin sensitivity and a reduction in type 2 diabetes, 47 suggesting a role for estrogen in regulating insulin sensitivity. The studies highlight underlying sex differences in metabolism that may contribute to male-female differences in disease progression. Hyperglycaemia also contributes to the increased incidence of heart failure with insulin resistance and diabetes. [25] [26] [27] [48] [49] [50] For example, hyperglycaemia can increase the incidence of vascular disease and atherosclerosis. [51] [52] [53] [54] [55] [56] Glycation, which increases with hyperglycaemia and is associated with hypertrophy and heart failure, may be a contributing factor. [57] [58] [59] [60] There is recent evidence that controlling blood glucose levels is beneficial in heart failure and diabetes. Results from the EMBAG-REG clinical trial indicate that in type 2 diabetics a sodium glucose cotransporter inhibitor, which lowers plasma glucose levels, reduces the number of deaths attributed to heart failure. 61, 62 Elevated levels of plasma glucose lead to glycation of lipids and proteins which are referred to as advanced glycation end products (AGEs) also play a role in diabetic cardiomyopathy. AGE can crosslink to extracellular matrix and is an important factor in vascular disease associated with diabetes. A receptor for AGE (RAGE), which is related to the immunoglobulin superfamily, is present on vasculature and other cell types. Soluble RAGE (sRAGE) is located in serum, where it binds AGE and blocks it from activating RAGE and is therefore thought to be protective. Females have lower levels of protective sRAGE, which may play a role in increased incidence of diabetic cardiomyopathy in comparison to males. During hypertrophy, shifts in energy metabolism are consistent with a reversion to a foetal gene program. For example, a rise in glycolysis is observed in hypertrophied hearts which can contribute to a decline in cardiac function and the development of heart failure. [63] [64] [65] [66] [67] [68] [69] [70] In general, in severe heart failure a rise in glycolysis is accompanied by a decrease in overall mitochondrial metabolism, including a decline in fatty acid oxidation as well as glucose and lactate oxidation rates. 65, [67] [68] [69] [70] 48 Energy metabolism in HFpEF is not as well-studied, but data show an increase in glycolysis relative to mitochondrial oxidative metabolism including glucose oxidation. 65, 71, 72 One protein that has been suggested to be a key regulator of metabolic changes in both diabetes and hypertrophy is peroxisome proliferator-activated receptor (PPARa). PPARa is known to regulate fatty acid oxidation and has been well-documented to play a role in cardiac hypertrophy and dysfunction. 73 Therefore, PPARa may play a role in sex differences in metabolic cardiomyopathies. Most, 74, 75 but not all 76 studies report a decrease in PPARa with hypertrophy.
Fenofibrate, a PPARa agonist, has been shown to reduce hypertrophy. 77, 78 However, treatment with a different PPARa agonist, WY-14,643, restored fatty acid oxidation during hypertrophy and reversed the increase in skeletal alpha actin, but it did not reduce cardiac hypertrophy and resulted in increased contractile dysfunction. 75 It was concluded that a decrease in PPARa during hypertrophy is essential for the maintenance of contractile function in hypertrophy. Hypertrophy has also been assessed in mice lacking PPARa and mice overexpressing PPARa. Mice with cardiac specific overexpression of PPARa exhibit cardiac hypertrophy and a phenotype similar to that seen with diabetic cardiomyopathy. 79 This includes elevated fatty acid oxidation and decreased glucose oxidation 79 compared to WT mice. The elevation in cardiac fatty acid oxidation observed in diabetes is also associated with Sex differences in metabolic cardiomyopathy an elevation in PPARa. 80 Furthermore, compared to WT mice, both male and female mice with PPARa overexpression developed hypertrophy and systolic dysfunction but no sex differences were reported. 79 Consistent with a role for PPARa in regulating fatty acid oxidation, PPARa-KO mice have a decrease in fatty acid oxidation. Most studies report no baseline dysfunction in PPARa-KO mice, 81 but male PPARa-KO mice subjected to transaortic constriction have increased hypertrophy and a greater depression in ejection fraction compared to WT mice; 82 females were not studied. Oka et al. 76 reported that haploinsufficiency of PPARa attenuated pressure overload induced hypertrophy. Taken together the data suggest that there is a sweet spot for PPARa levels and activity; that too much or too little PPARa can lead to hypertrophy. Also of interest are data indicating that there are sex differences in the regulation of PPARa. [83] [84] [85] PPARa expression in the heart at baseline is lower in female mice compared to male mice. 84 Interestingly, in PPARa-KO mice inhibition of carnitine palmitoyltransferase 1 resulted in death of 100% of the male mice, but only 25% of the female mice, suggesting sex differences in the response to changes in PPARa. 86 
Calcium handling
Alterations in calcium handling are well-documented to occur in hypertrophy and HFrEF. 87 Enhancing calcium uptake into the sarcoplasmic reticulum (SR) by increasing sarco/endoplasmic reticulum Ca 2þ -ATPase (SERCA) levels by gene therapy has been reported in animal studies to be beneficial, 88, 89 although a recent clinical trial failed to show beneficial effects. 90 In contrast to HFrEF, there are few studies examining calcium handling in HFpEF, largely due to the scarcity of animal models. 91 However, calcium handling and cardiac function have been shown to be altered in response to changes in metabolism. For example, metabolic syndrome, a cluster of metabolic disorders that increase heart disease risk, has been shown to increase diastolic calcium levels and increase SR calcium leak. 92 Dietary fructose has been highlighted as altering calcium handling at the cardiomyocyte level. 93 In diabetic animal models, whole hearts and isolated cardiomyocytes from diabetic animals have depressed contractility and slowed relaxation associated with decreased calcium handling by the SR. 94, 95 Though little is known about how diabetes alters calcium handling differently between the sexes, recent research suggests that SR calcium release units are different in male and female diabetic animals. 96 Sex differences in basal calcium handling, discussed below, may underlie differences observed in heart failure and diabetic cardiomyopathy between men and women. Sex differences in the expression and regulation of many ion channels have been reported, [34] [35] [36] which could all contribute to differences in contractility and relaxation. [34] [35] [36] Basal calcium handling and excitationcontraction coupling have also been found to differ between males and females (for a recent review see 97 ) . Although there is variability among studies, a reduced calcium transient in females is often observed. 97 Parks et al. 98 investigated the basis for reduced calcium transients and found altered SR calcium release due to sex differences in cyclic AMP and protein kinase A. Contractile reserve has also been shown to be reduced in females. 99 Consistent with altered contractile reserve, a number of studies have documented sex differences in calcium handling following isoproterenol stimulation. Curl et al. 100 have reported that isoproterenol leads to smaller calcium transients in females compared to males. Chen et al. 101 used an NMR sensitive SR calcium indicator to measure SR calcium in beating perfused rabbit hearts and found no sex differences at baseline, but found that addition of isoproterenol resulted in a smaller rise in SR calcium in females compared to males. Further, Hoeker et al. 102 investigated sex differences in action potential duration, calcium transient duration, and the calcium transient decay constant following isoproterenol stimulation and found significantly smaller changes in action potential duration and calcium transient decay in females. Bell et al. 103 showed sex differences in hypertrophic cardiomyocytes in response to beta adrenergic stimulation. Altered basal calcium handling and contractile reserve in males and females could contribute to differences in the progression of cardiomyopathies between the sexes, including diabetic cardiomyopathy. The mechanism responsible for the sex difference in response to isoproterenol is likely multifactorial, but sex differences in nitric oxide synthase (NOS) and NO signalling have been shown to play a role. Cardiac NOS is well-established to play a role in modulating the response to isoproterenol. 104, 105 Interestingly, there are sex differences in NO modulation of isoproterenol-induced SR calcium handling. 101 eNOS and nNOS are increased in female cardiomyocytes 106 with a concomitant increase in S-nitrosylation (SNO), 106, 107 an NO dependent post-translational modification. NO and SNO are documented to regulate calcium handling. 108, 109 In cardiac myocytes, eNOS, which is usually localized to the plasma membrane, can S-nitrosylate and inhibit the L-type calcium channel. 106 In contrast, nNOS is localized to the SR where it S-nitrosylates (which will also promote S-glutathiolation) SERCA leading to its activation. SR localized nNOS can also S-nitrosylate the ryanodine calcium release channel, further enhancing SR calcium cycling. Both nNOS and eNOS knockout mice have been developed and both show altered calcium handling, 108, 109 consistent with the hypothesis that sex differences in NOS can lead to sex differences in calcium handling. Taken together, calcium handling and calcium dynamics show sex differences and these differences likely contribute to sex differences in the development of hypertrophy. There is also a wealth of data suggesting a role for NO in altered calcium regulation during hypertrophy and heart failure. 110 A potential central role for NOS in mediating sex differences in cardiac physiology and pathophysiology will be discussed later in this review.
Structure differences
Structural differences are also thought to play a role in the prevalence of HFpEF as opposed to HFrEF. Females have baseline differences in collagen and its regulation, 37, 111 and the remodelling following hypertrophy differs in males and females. 112, 113 Myocyte death leads to replacement by fibroblasts with an increase in collagen deposition. This increase in collagen (and potential differences in the type of collagen) leads to ventricle stiffness. Diabetic cardiomyopathy promotes fibrosis and an increase in collagen type I and type III. Sex and age-dependent regulation of collagen has been reported in humans. 111 In young women, collagen types I and III are lower than in men, but with age the trend reverses and now women have higher collagen I and III levels compared to men. Treatment of fibroblasts with estrogen leads to an increase in collagen I and III in males, but a decrease in these collagens in females. 114 Estrogen receptor (ER) beta is reported to regulate collagen; mice with overexpression of ER-beta show a decrease in deposition of collagen I and III following hypertrophic stimuli. 115 Sex differences in collagen also occur during the development of hypertrophy. Michel reported that chronic isoproterenol stimulation in spontaneously hypertensive rats leads to an increase in collagen deposition in males but not in females. 112 These sex differences in regulation of collagen likely contribute to the altered remodelling in males vs. females following hypertrophy. In addition to sex differences in collagen, sex differences in contractile proteins have also been reported. 33 McKee et al. 116 have reported sex differences in myofilaments in hypertrophic cardiomyopathy and differences in myofilaments could also play a role in sex differences in HFpEF. Consistent with this concept, Reiser and Moravec have described sex differences in myosin heavy chain isoforms. 117 Najafi et al. 118 have reported sex differences in response to exercise in transgenic mice with a MYBPC3 knock-in mutation which is associated with hypertrophic cardiomyopathy.
Mechanisms underlying sex differences in metabolic cardiomyopathies

Sex differences in gene expression
It has become clear that there are a large number of sex differences in gene expression in the heart 33-39 and these differences likely underlie the sex differences in hypertrophy. Estrogen has been reported to regulate expression of PGC-1a, a key metabolic regulator. 119 Sex differences in PPARa expression have also been reported, 84 along with sex differences in a large number of ion channels and transporters, which could all contribute to differences in contractility. [34] [35] [36] As discussed previously there are also sex differences in expression of collagen and contractile proteins. 37 Thus, it is not surprising that there are sex differences in response to hypertrophic stress. Sex hormones such as estrogen play a role in the sex differences in gene expression, but the X and Y chromosomes and alterations in X-inactivation can also play a role. A recent study examined the effect of the number of X chromosomes on ischemia-reperfusion injury in a model that is independent of gonadal hormones and found that compared to XY mice that mice with two X chromosomes have increased ischemia-reperfusion injury. 120 
Sex differences in signalling pathways. A central role for NOS and PPARa
Sex differences in gene expression ultimately lead to differences in signalling pathways which alter the response to hypertrophic stimuli. The sex differences in metabolic cardiomyopathy may simply be due to the sum of sex differences in gene expression of metabolic, calcium handling, and structural proteins. However, it is worth considering whether there might be a primary driver of these sex differences. Sex differences in calcium-activated eNOS and nNOS have been demonstrated in a number of studies, 106, 121 and the NO dependent post-translational modification, SNO is higher at baseline in females compared to males. 106, 107, 122 Differences in SNO have also been observed in human heart failure samples. 122 NO/SNO regulates metabolism, calcium homeostasis, and contractility as well as responses to hypertrophy. 101, 108, 109, [123] [124] [125] [126] [127] [128] Alterations in NO signalling have also been shown to play a key role in regulating endothelial function. [129] [130] [131] Thus, as illustrated in Figure 1 , Tables 1 and Tables 2, sex differences in NO/SNO signalling could contribute to sex differences in metabolism, excitation-contraction coupling, and the development of fibrosis associated with hypertrophy. NO/SNO regulation of calcium handling has been discussed in Section 2. NO also plays a key role in metabolic regulation and response to insulin resistance, 132 and modulating NO signalling blocks the development of fibrosis following hypertrophic stimuli. 124, 133 Mice lacking eNOS develop insulin resistance. 126, 127 Further, eNOS overexpression has been shown to prevent diet-induced obesity and lead to an up-regulation of PPARa in adipose tissue. 125 The increase in free fatty acids that typically occurs with metabolic syndrome would further activate PPARa, which is differentially expressed and regulated in males and females. Metabolic disease and obesity lead to a pro-inflammatory state and an increase in oxidative stress. 30 The increase in oxidative stress also leads to an increase in angiotensin II and endothelin, which promote collagen and extracellular matrix deposition contributing to LV stiffness. Sex differences in collagen regulation could also contribute to sex differences in metabolic cardiomyopathy. Oxidative stress promotes uncoupling of eNOS such that it generates additional reactive oxygen species (ROS) rather than NO. 124, 133 Uncoupled NOS can contribute to insulin resistance 132 and diastolic dysfunction in HFpEF. 124 As females have increased baseline levels of NOS this would result in a further increase in ROS and this might increase the susceptibility of females to hypertrophy and failure in the setting of metabolic cardiomyopathy. Addition of tetrahydrobioptrin (BH4), which enhances NOS coupling, has been shown to reduce diastolic dysfunction 124 and hypertrophy induced fibrosis 123 ; although a recent study suggested that the protective effect of BH4 might be related to macrophage NOS coupling 134 . Taken together these data support a hypothesis that sex differences in NOS might be a central regulator of sex differences in response to metabolic cardiomyopathy. NOS uncoupling that occurs with metabolic cardiomyopathies would alter calcium handling, alter metabolism and promote fibrosis. As females have increased baseline NOS they would be more susceptible to NOS uncoupling. Several potential targets of NO/SNO have been shown to regulate calcium handing and contractility, including SERCA, Ltype calcium channel and the ryanodine receptor, (RyR). NO has also been demonstrated to increase mitochondrial biogenesis and regulate metabolism, although the precise target proteins need to be better defined. SNO of a number of metabolic enzymes such as GAPDH, aKGDH, and aconitase are well described but their role in regulating metabolism needs further study.
Sex differences in response to drug treatment
These sex differences in hypertrophy and heart failure and the mechanisms regulating hypertrophy and heart failure need to be considered in Figure 1 Under baseline conditions female hearts have a higher expression of NOS which is associated with lower ROS levels, increased insulin sensitivity and a lower PPARa expression. NOS also inhibits the L-type Ca channel and activates SERCA thereby maintaining normal diastolic Ca levels. Diabetes and other metabolic cardiomyopathies increase ROS leading to NOS uncoupling which in turn upon activation of NOS leads to increased ROS, Ca dysregulation leading to an increase in diastolic Ca, altered metabolism and decreased insulin sensitivity. As there are sex differences in NOS and PPARa, these pathways exhibit sexual dimorphic responses.
drug therapies for these diseases. Consistent with sex differences in metabolism, sex differences in response to drugs such as metformin 45 have been reported. Type 2 diabetic male and female patients were treated with metformin, and fatty acid clearance and utilization were measured. Males showed an increase in myocardial fatty acid oxidation, but no change was observed in females. Sex differences in response to sildenafil have also been reported. 135 In animal studies, sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, reduced hypertrophy-induced cardiac remodelling. 136, 137 Sildenafil was also shown to reduce pathological remodelling in a small clinical study; 138 however, the cardioprotective effect of this drug was not significant in a large placebo-controlled clinical trial. 139 As the animal studies were performed on male animals whereas the clinical trial included both males and females, Sasaki and colleagues considered whether a sex difference in response to sildenafil might help explain the lack of protection in the clinical trial. They found that the efficacy of PDE5 inhibition by sildenafil in female mice requires estrogen. 140 Induction of cardiac stress in male and intact female mice resulted in increased activation of protein kinase G (PKG) signalling, which was further enhanced by sildenafil. PKG activity was not enhanced in ovariectomized female mice as a result of cardiac stress, but administration of estrogen restored PKG activation and enhancement by sildenafil. These data highlight the importance of considering sex-specific differences and drug responses in clinical trial design.
Summary and conclusions
Although heart failure and cardiomyopathy are generally less prevalent in women, cardiomyopathies with a metabolic link such as diabetic cardiomyopathy and HFpEF show increased prevalence in women. We considered a role for sex differences in metabolism and calcium handling in mediating these sex differences in metabolic cardiomyopathies. NOS and PPARa are known to exhibit baseline sex differences and NOS and PPARa are also well-known to regulate metabolism and calcium handling. Interplay between PPARa and NO has also been reported. For example, nitrate has been shown to increase fatty acid oxidation, but this does not occur in mice lacking PPARa. 141 As NOS and PPARa have also been proposed to mediate the development of hypertrophy and heart failure, we propose a role for these signalling pathways in regulating sex differences in metabolic cardiomyopathies. It is tempting to speculate that sex differences in NOS might be a central regulator of sex differences in response to metabolic cardiomyopathy. NOS uncoupling that occurs with metabolic cardiomyopathies would alter calcium handling, alter metabolism and promote fibrosis. As females have increased baseline NOS they would be more susceptible to NOS uncoupling. Further studies will be needed to test this hypothesis. 
